Immunosuppressive medications for renal transplantation: A multiple choice question

Kidney International

Volumn 59, Issue 1, 2001, Pages 388-402

  Danovitch, Gabriel M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute rejection; Basiliximab; CD25 receptor; Cyclosporine; Daclizumab; Mycophenolate mofetil; Sirolimus; Tacrolimus

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; CLONIDINE; COTRIMOXAZOLE; CYCLOSPORIN; CYCLOSPORIN A; DILTIAZEM; ENALAPRIL; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; GRAFT SURVIVAL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

EID: 0035162914     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.00501.x     Document Type: Article

References (87)

1. Kidney transplantation: A history
2. Cyclosporin A initially as the only immunosuppressant in 36 recipients of cadaveric organs
3. Cyclosporin-associated chronic nephropathy
4. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment of recipients of renal allografts
5. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
6. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
7. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients
8. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with Basiliximab, a chimeric anti-interleukin-2-receptot monoclonal antibody
9. Reduction of acute renal allograft rejection by daclizumab
10. Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus ATGAM in the treatment of acute graft rejection episodes after renal transplantation
11. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation
12. Efficacy of sirolimus compared with azathioprine for reduction of acute allograft rejection: A randomized multicentre study
13. Immunologic factors: The major risk for decreased long-term renal allograft survival
14. The first two post-transplant months
15. Mycophenolate mofetil in cadaveric renal transplantation
16. Improved graft survival after renal transplantation in the United States, 1988 to 1996
17. Design of trials of methods to reduce late allograft loss: The price of success
18. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
19. Improving the success of organ transplantation
20. The epidemic of cardiovascular disease in chronic renal disease: A challenge to the transplant physician
21. Choice of immunosuppressive drugs and individualization of immunosuppressive therapy for kidney transplant patients
22. Cyclosporin or tacrolimus: Which agent to choose?
23. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
24. Intragraft TGFβ mRNA. A correlate of interstitial fibrosis and chronic allograft nephropathy
25. Cyclosporine induces cancer progression by a cell-autonomous mechanism
26. Effect of immunosuppressive therapy on graft half-life projections
27. Review of immunosuppressive usage in pancreas transplantation
28. Two distinct cDNAs for human IMP dehydrogenase
29. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression
30. Sirolimus-tacrolimus combination immunosuppression
31. The effect of antilymphocyte induction therapy on renal allograft survival
32. Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression
33. Improved cadaveric renal transplant outcome in children
34. Delayed graft function in renal transplantation: Etiology, management and long-term significance
35. Immunosuppressive medications and protocols for kidney transplantation
36. A randomized, double-blinded comparison of thymoglobulin versus ATGAM for induction immunosuppressive therapy in adult renal transplant recipients
37. Infection in organ-transplant recipients
38. Epstein-Barr virus-induced post transplant lymphoproliferative disorders
39. Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine
40. Clinically significant drug interactions with cyclosporine
41. Improvement of cadaver renal transplant outcomes with verapamil: A review
42. Effect of pravastatin on outcomes after cardiac transplantation
43. The effect of pravastatin on acute rejection after kidney transplantation: A pilot study
44. Long-term survival in renal transplant recipients with graft function
45. Post-transplant lymphoproliferative disease in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression
46. Sirolimus reduces the incidence of acute rejection episodes despite low cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial
47. Corticosteroid withdrawal in solid organ transplantation
48. Immunosuppressant induced metabolic toxicities
49. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: A randomized study
50. Elective cyclosporine withdrawal after renal transplantation: A meta-analysis
51. Sirolimus (rapamicin)-based therapy in human renal transplantation
52. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute allograft rejection in renal allograft recipients
53. Infectious complications in geriatric renal transplant patients: Comparison of two immunosuppressive protocols
54. Mycophenolate mofetil in renal allograft recipients
55. Racial differences in the survival of cadaveric renal allografts: Overriding effects of HLA matching and socioeconomic factors
56. Racial differences in renal allograft survival: The role of systemic hypertension
57. Renal transplantation outcomes in African-American patients
58. Relationship between cyclosporine bioavailability and clinical outcome in renal transplant recipients
59. Diagnosis and therapy of graft dysfunction
60. HLA matching determines susceptibility to harmful effects of delayed graft function in renal transplant recipients
61. Effect of initial slow graft function on renal allograft rejection and survival
62. Delayed graft function, acute rejection and outcome after cadaver renal transplantation
63. Significance of donor age effect in kidney transplantation
64. Should I accept this kidney?
65. Hypertension in renal allograft recipients may be conveyed by cadaveric kidneys from older donors with subarachnoid hemorrhage
66. Glomerulosclerosis as a determinant of post transplant function in older donor renal allografts
67. Double renal transplants from marginal donors: 2-year donor results
68. Early experience with dual kidney transplantation
69. Proportions of glomerulosclerosis in procurement wedge renal biopsy cannot alone discriminate for acceptance of marginal donors
70. Diabetes mellitus after renal transplantation
71. ACE inhibitors and angiotensin II antagonists in renal transplantation: An analysis of safety and efficacy
72. 1 in transplant patients with chronic allograft nephropathy
73. Chronic renal allograft rejection: Immunologic and nonimmunologic risk factors
74. Rethinking chronic allograft nephropathy: The concept of accelerated senescence
75. Nephrotoxicity of immunosuppressive drugs: Long term consequences and challenges for the future
76. Chronic renal allograft rejection: No response to mycophenolate mofetil
77. A novel approach to the treatment of chronic allograft nephropathy
78. Genetic regulation of cytokine synthesis: Consequences for acute and chronic rejection
79. Beneficial effects of treatment of early subclinical rejection: A randomized study
80. Testing for polyoma virus type BK DNA in plasma to identify renal allograft recipients with viral nephropathy
81. The evaluation of renal transplant candidates: Clinical practice guidelines
82. Late renal allograft loss: Noncompliance masquerading as chronic rejection
83. Mishandling the gift of life: Noncompliance in renal transplant patients
84. High survival rates of kidney transplants from spousal and living unrelated donors
85. Expanding the kidney donor pool
86. Islet transplantation in seven patients with type I diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
87. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T-cells and induction of peripheral allograft tolerance